Oxford Medical Simulation Limited


Acorah Software Products - Accounts Production 14.6.300 false true true 31 January 2023 1 February 2022 false 1 February 2023 31 January 2024 31 January 2024 10587122 Dr K N Henke Mr L R Hurst Mr K P Koenig Mr F N Morandi Dr J Pottle Mr M W Wallace Miss J Vazanova (Chair) iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10587122 2023-01-31 10587122 2024-01-31 10587122 2023-02-01 2024-01-31 10587122 frs-core:CurrentFinancialInstruments 2024-01-31 10587122 frs-core:ComputerEquipment 2024-01-31 10587122 frs-core:ComputerEquipment 2023-02-01 2024-01-31 10587122 frs-core:ComputerEquipment 2023-01-31 10587122 frs-core:PlantMachinery 2024-01-31 10587122 frs-core:PlantMachinery 2023-02-01 2024-01-31 10587122 frs-core:PlantMachinery 2023-01-31 10587122 frs-core:SharePremium 2024-01-31 10587122 frs-core:ShareCapital 2024-01-31 10587122 frs-core:RetainedEarningsAccumulatedLosses 2024-01-31 10587122 frs-bus:PrivateLimitedCompanyLtd 2023-02-01 2024-01-31 10587122 frs-bus:FilletedAccounts 2023-02-01 2024-01-31 10587122 frs-bus:SmallEntities 2023-02-01 2024-01-31 10587122 frs-bus:AuditExempt-NoAccountantsReport 2023-02-01 2024-01-31 10587122 frs-bus:SmallCompaniesRegimeForAccounts 2023-02-01 2024-01-31 10587122 frs-bus:OrdinaryShareClass1 2023-02-01 2024-01-31 10587122 frs-bus:OrdinaryShareClass1 2024-01-31 10587122 frs-bus:PreferenceShareClass1 2023-02-01 2024-01-31 10587122 frs-bus:PreferenceShareClass1 2024-01-31 10587122 frs-bus:Director1 2023-02-01 2024-01-31 10587122 frs-bus:Director2 2023-02-01 2024-01-31 10587122 frs-bus:Director3 2023-02-01 2024-01-31 10587122 frs-bus:Director4 2023-02-01 2024-01-31 10587122 frs-bus:Director5 2023-02-01 2024-01-31 10587122 frs-bus:Director6 2023-02-01 2024-01-31 10587122 frs-bus:Director7 2023-02-01 2024-01-31 10587122 frs-countries:EnglandWales 2023-02-01 2024-01-31 10587122 2022-01-31 10587122 2023-01-31 10587122 2022-02-01 2023-01-31 10587122 frs-core:CurrentFinancialInstruments 2023-01-31 10587122 frs-core:SharePremium 2023-01-31 10587122 frs-core:ShareCapital 2023-01-31 10587122 frs-core:RetainedEarningsAccumulatedLosses 2023-01-31 10587122 frs-bus:OrdinaryShareClass1 2022-02-01 2023-01-31 10587122 frs-bus:PreferenceShareClass1 2022-02-01 2023-01-31
Registered number: 10587122
Oxford Medical Simulation Limited
Financial Statements
For The Year Ended 31 January 2024
Financial Statements
Contents
Page
Statement of Financial Position 1—2
Notes to the Financial Statements 3—6
Page 1
Statement of Financial Position
Registered number: 10587122
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 127,867 85,511
127,867 85,511
CURRENT ASSETS
Debtors 5 4,250,303 3,561,263
Cash at bank and in hand 8,906,635 1,022,637
13,156,938 4,583,900
Creditors: Amounts Falling Due Within One Year 6 (3,024,482 ) (2,813,804 )
NET CURRENT ASSETS (LIABILITIES) 10,132,456 1,770,096
TOTAL ASSETS LESS CURRENT LIABILITIES 10,260,323 1,855,607
NET ASSETS 10,260,323 1,855,607
CAPITAL AND RESERVES
Called up share capital 7 34 26
Share premium account 15,648,716 5,790,199
Income Statement (5,388,427 ) (3,934,618 )
SHAREHOLDERS' FUNDS 10,260,323 1,855,607
Page 1
Page 2
For the year ending 31 January 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Income Statement.
On behalf of the board
Mr M W Wallace
Director
31 May 2024
The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Oxford Medical Simulation Limited is a private company, limited by shares, incorporated in England & Wales, registered number 10587122 . The registered office is 201 Borough High Street, London, SE1 1JA.

The presentation currency of the financial statements is the Pound Sterling (£).
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
Whilst the business has been loss making in the financial year, the Directors regularly review  the cash position and forecast and believe there is sufficient funds to pay liabilities as they fall  due. As such the Directors agree the going concern basis is the appropriate method to prepare these financial statements.
2.3. Significant judgements and estimations
The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates if necessary. It also requires management to exercise judgement in applying the company accounting policies.
2.4. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
2.5. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Plant & Machinery Straight line over 2 years
Computer Equipment Straight line over 3 years
2.6. Financial Instruments
The company has elected to apply the provisions of Section 11 Basic Financial Instruments and Section 12 Other Financial Instruments Issues of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method, unless the arrangement consitutes a financing transaction, where the transaction is measured at the present value if the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
...CONTINUED
Page 3
Page 4
2.6. Financial Instruments - continued
Classification of financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitute and financing transaction, where the debt instrument is measured at the present value of future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditor are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently at amortised cost using the effective interest method.
2.7. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the statement of financial position date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.8. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
2.9. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the income statement as they become payable in accordance with the rules of the scheme.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 54 (2023: 36)
54 36
Page 4
Page 5
4. Tangible Assets
Plant & Machinery Computer Equipment Total
£ £ £
Cost
As at 1 February 2023 66,195 149,296 215,491
Additions 6,396 95,327 101,723
As at 31 January 2024 72,591 244,623 317,214
Depreciation
As at 1 February 2023 62,709 67,271 129,980
Provided during the period 5,400 53,967 59,367
As at 31 January 2024 68,109 121,238 189,347
Net Book Value
As at 31 January 2024 4,482 123,385 127,867
As at 1 February 2023 3,486 82,025 85,511
5. Debtors
2024 2023
£ £
Due within one year
Trade debtors 354,102 295,705
Amounts owed by group undertakings 3,665,955 2,731,027
Other debtors 230,246 534,531
4,250,303 3,561,263
6. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Trade creditors 132,840 40,371
Other creditors 2,780,905 2,681,316
Taxation and social security 110,737 92,117
3,024,482 2,813,804
7. Share Capital
2024 2023
Allotted, called up and fully paid £ £
267,808 Ordinary Shares of £ 0.0001 each 27 26
Preference Shares
2024 2023
Allotted, called up and fully paid £ £
61,696 Preference Shares of £ 0.0001 each 7 -
8. Share-based payment transactions
EMI Scheme

The Company operates an Approved EMI Share Option Plan where certain employees are granted options to purchase shares in the Company. On exercise of the options by the employee, the Company issues new shares. In the year ended 31 January 2024, 5,000 options were granted at an exercise price of £19.00. The existing options vest equally over the remaining vesting period.
...CONTINUED
Page 5
Page 6
All Options issued to date are over Ordinary Shares.
The following table illustrates the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year under the Approved EMI Share Option Plan.
2024
2024
2023
2023
No.
image
WAEP £
image
No.
image
WAEP £
image
Outstanding as at 1 February
2,000
16.19
1,000
13.38
Granted in the year
5,000
19.00
1,000
19.00
Lapsed in the year
-
-
-
-
Outstanding at 31 January 
7,000
image
18.20
image
2,000
image
16.19
image
Exercisable at 31 January
2,333
image
16.59
image
958
image
13.80
image

The Company is unable to directly measure the fair value of employee services received. Instead the fair value of the share options granted during the year is determined using the Black-Scholes model. The model is internationally recognised as being appropriate to value employee share schemes similar to the scheme the Company have in place. Since the options are granted to employees at the fair market value at the time of grant, the fair value as calculated using the Black-Scholes model is entirely immaterial to the users of the financial statements and as such the Directors have taken the decision not to reflect any charge to profit for the grant of EMI options.

Unapproved Scheme

The Company also operates an unpproved Share Option Scheme, where certain individuals are granted options to purchase shares in the Company. Under this plan, individuals are granted options over Ordinary shares with options vesting under differing schedules. In the year ended 31 January 2024, 1,000 options were granted.
All Options issued are over Ordinary Shares.
The following table illustrates the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year under the unapproved Share Option Plan.
2024
2024
2023
2023
No.
image
WAEP £
image
No.
image
WAEP £
image
Outstanding as at 1 February
6,735
84.70
6,735
84.70
Granted during the year
1,000
35.74
-
84.70
Outstanding at 31 January
7,735
image
78.37
image
6,735
image
84.70
image
Exercisable at 31 January
2,920
image
84.70
image
1,572
image
84.70
image

The Company is unable to directly measure the fair value of employee services received. Instead the fair value of the share options granted during the year is determined using the Black-Scholes model. The model is internationally recognised as being appropriate to value employee share schemes similar to the scheme the Company have in place. charge to profit for the grant of EMI options.
Page 6